

# PharmacareNEWS

## inside

### Nova Scotia Formulary Updates

#### Criteria Update

- Nubeqa (darolutamide)

#### Change in Benefit Status

- Alfuzosin
- Cotazym
- Cotazym ECS
- Creon
- Cyclomen
- Pancrease
- Viokace

#### Diabetic Supplies Benefit List Update

#### Pharmacare News Bulletins

## Nova Scotia Formulary Updates

### Criteria Update

The following new indication and updated criteria for an existing indication is effective **February 1, 2024**.

PRODUCT	STRENGTH	DIN	PRESCRIBER	BENEFIT STATUS	MFR
<b>Nubeqa (darolutamide)</b>	300mg Tab	02496348	DNP	E (SFC)	BAY

#### Criteria **Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)**

- In combination with androgen deprivation therapy (ADT) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who have no detectable distant metastases (M0) by either CT, MRI or technetium-99m bone scan and who are at high risk of developing metastases<sup>1</sup>.

<sup>1</sup>High risk of developing metastases is defined as a prostate-specific antigen (PSA) doubling time of  $\leq 10$  months during continuous ADT.

#### Clinical Notes:

- Patients should have a good performance status.
- Treatment should continue until radiographic disease progression or unacceptable toxicity.
- Castration-resistance must be demonstrated during continuous ADT and is defined as 3 PSA rises at least one week apart, with the last PSA greater than 2 ng/mL.
- Castrate levels of testosterone must be maintained.
- Patients with N1 disease, pelvic lymph nodes less than 2cm in short axis located below the aortic bifurcation are eligible for darolutamide.
- Darolutamide will not be funded for patients who experience disease progression on apalutamide or enzalutamide.

Criteria Update Continued...

PRODUCT	STRENGTH	DIN	PRESCRIBER	BENEFIT STATUS	MFR
Nubeqa (darolutamide)	300mg Tab	02496348	DNP	E (SFC)	BAY
Criteria	<p><b>Metastatic Castration-Sensitive Prostate Cancer (mCSPC)</b></p> <ul style="list-style-type: none"> <li>In combination with docetaxel and androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).</li> </ul> <p><b>Clinical Notes:</b></p> <ul style="list-style-type: none"> <li>Patients should have a good performance status and be eligible for chemotherapy.</li> <li>Treatment should continue until disease progression or unacceptable toxicity.</li> <li>Patients should have had no prior ADT in the metastatic setting, or are within 6 months of initiating ADT in the metastatic setting with no disease progression.</li> <li>Patients will be eligible if they received ADT in the non-metastatic setting as long as at least a one year interval has passed since completion.</li> <li>Darolutamide will not be funded for patients who experience disease progression on enzalutamide or apalutamide.</li> </ul>				

### Change in Benefit Status

Effective **February 1, 2024**, the following products will be added as a benefit in the Nova Scotia Formulary. The benefit status within the Pharmacare Programs is indicated.

PRODUCT	STRENGTH	DIN	PRESCRIBER	BENEFIT STATUS	MFR
Alfuzosin	10mg Tab	Various	DNP	SF	VAR

Effective **February 1, 2024**, the following products will be added to the Drug Assistance for Cancer Patients Program.

PRODUCT	STRENGTH	DIN	PRESCRIBER	BENEFIT STATUS	MFR
Cotazym	8000u Cap	00263818	DNP	SFC	ORG
Cotazym ECS	Various	Various	DNP	SFC	ORG
Creon	Various	Various	DNP	SFC	BGP
Cyclomen	Various	Various	DNP	SFC	SAV
Pancrease	Various	Various	DNP	SFC	VVS
Viokace	Various	Various	DNP	SFC	ARN

## Diabetic Supplies Benefit List Update

Effective **February 1, 2024**, the following products will no longer be covered under the Nova Scotia Pharmacare Programs.

PRODUCT	DIN	PRESCRIBER	BENEFIT STATUS	MFR
Medi+Sure BG Test Strips (100)	97799403	N/A	<b>Not Insured</b>	MSR
MediSure Empower Test Strips (100)	97799053	N/A	<b>Not Insured</b>	MSR
MediSure Empower Test Strips (50)	97799054	N/A	<b>Not Insured</b>	MSR
Medi+Sure Soft 30G Twist Lancet	97799388	N/A	<b>Not Insured</b>	MSR
Medi+Sure Soft 33G Twist Lancet	97799389	N/A	<b>Not Insured</b>	MSR

## Pharmacare News Bulletins

The Pharmacare News Bulletins are an important source of information containing recent changes to the Pharmacare Programs, including the Formulary.

Did you know you know electronic versions of the Pharmacare News Bulletins are available at <https://novascotia.ca/dhw/pharmacare/pharmacare-news-bulletins.asp>.

Currently, bulletins are also mailed. If you prefer to review the electronic versions and wish to have your mailing address removed from our mailing list, please send an email to [BC\\_MSI\\_PharmAdmin@medavie.bluecross.ca](mailto:BC_MSI_PharmAdmin@medavie.bluecross.ca) with your Name and MSI Provider Number.

## Legend

PRESCRIBER CODES	BENEFIT STATUS	MANUFACTURER CODES
D - Physician / Dentist	S - Seniors' Pharmacare	ARN - Accelera Pharma Canada Inc
N - Nurse Practitioner	F - Community Services Pharmacare	BAY - Bayer Inc.
P - Pharmacist	- Family Pharmacare	BGP - BGP Pharma Inc
M - Midwife	C - Drug Assistance for Cancer Patients	MSR - Medisure Canada
O - Optometrist	D - Diabetes Assistance Program	ORG - Organon Canada LTD
	E - Exception status applies	SAV - Sanofi-Aventis Canada Inc.
		VAR - <i>various manufacturers</i>
		VVS - Vivus Inc